Merck & Co sets sights on oncology to drive long-term growth.
By Justin Burns, Analytics Analyst
6 May 2016
Merck & Co will seek to expand beyond its historically dominant presence in the diabetes market by adding additional focus to its oncology pipeline. Revenues in this therapy area is forecast to grow by $4.7bn between 2015 and 2025. Revenue growth will be driven almost exclusively by Keytruda (pembrolizumab), which has already been approved in melanoma and non-small cell lung cancer (NSCLC). Merck & Co will expand the potential for Keytruda in more than a dozen other indications, including colorectal cancer, breast cancer, gastric cancer, and head and neck cancer. Keytruda’s most significant potential lies in addressing patient populations in NSCLC and colorectal cancer. Datamonitor Healthcare expects both of these indications to hold blockbuster status for Keytruda.
Merck & Co has also augmented its early-stage oncology pipeline through the acquisitions of cCAM Biotherapeutics and IOmet Pharma. The acquisition of cCAM delivers several immunotherapy products to Merck & Co, including CM-24, a novel monoclonal antibody (mAb) targeting the immune checkpoint protein CEACAM1, which is currently under evaluation in a Phase I study for multiple tumor types. The IOmet acquisition adds several more preclinical immunotherapy candidates to Merck & Co’s pipeline, including IDO (indoleamine-2,3-dioxygenase 1), TDO (tryptophan-2,3-dioxygenase), and dual-acting IDO/TDO inhibitors.
Datamonitor Healthcare’s company analysis on Merck & Co explores global corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2015–25.
Get your free demo today – simply fill out the form to the right.